BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 9384697)

  • 1. Detection of minimal residual disease in acute leukemia patients.
    van Dongen JJ; Szczepański T; de Bruijn MA; van den Beemd MW; de Bruin-Versteeg S; Wijkhuijs JM; Tibbe GJ; van Gastel-Mol EJ; Groeneveld K; Hooijkaas H
    Cytokines Mol Ther; 1996 Jun; 2(2):121-33. PubMed ID: 9384697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction.
    van Dongen JJ; Breit TM; Adriaansen HJ; Beishuizen A; Hooijkaas H
    Leukemia; 1992; 6 Suppl 1():47-59. PubMed ID: 1548936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology.
    Nakao M; Janssen JW; Flohr T; Bartram CR
    Cancer Res; 2000 Jun; 60(12):3281-9. PubMed ID: 10866322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.
    Boeckx N; Willemse MJ; Szczepanski T; van der Velden VH; Langerak AW; Vandekerckhove P; van Dongen JJ
    Leukemia; 2002 Mar; 16(3):368-75. PubMed ID: 11896540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
    van der Velden VH; Hochhaus A; Cazzaniga G; Szczepanski T; Gabert J; van Dongen JJ
    Leukemia; 2003 Jun; 17(6):1013-34. PubMed ID: 12764363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
    Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia.
    Szczepański T; Flohr T; van der Velden VH; Bartram CR; van Dongen JJ
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):37-57. PubMed ID: 11987915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease.
    Breit TM; Beishuizen A; Ludwig WD; Mol EJ; Adriaansen HJ; van Wering ER; van Dongen JJ
    Leukemia; 1993 Dec; 7(12):2004-11. PubMed ID: 8255100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of clonal stability of minimal residual disease targets between 1st and 2nd relapse of childhood precursor B-cell acute lymphoblastic leukemia.
    Guggemos A; Eckert C; Szczepanski T; Hanel C; Taube T; van der Velden VH; Graf-Einsiedel H; Henze G; Seeger K
    Haematologica; 2003 Jul; 88(7):737-46. PubMed ID: 12857551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid detection of gammaT cell receptor gene rearrangements in acute lymphoblastic leukemia by electrophoresis and silver staining: implications for detection of minimal residual disease.
    Valetto A; Lanciotti M; Di Martino D; Anselmi G; Bottini F; Mori P; Candiano G
    Electrophoresis; 1998 Jun; 19(8-9):1385-7. PubMed ID: 9694286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of minimal residual disease by means of FISH and PCR methods and its clinical evaluation].
    Misawa S; Taniwaki M; Yokota S
    Rinsho Ketsueki; 1995 Apr; 36(4):293-8. PubMed ID: 7783332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of minimal residual diseases in B-cell tumors using PCR specific for the immunoglobulin heavy chain gene].
    Matolcsy A; Borbényi Z; Demeter J; Egyed M; Fekete S; Földi J; Gergely L; Kajtár P; Kelényi G; Kiss A; László T; Lehoczky D; Losonczy H; Nagy M; Pál K; Pálóczy K; Radványi G; Semsei I; Varga G; Udvardy M
    Orv Hetil; 2000 Jun; 141(25):1403-6. PubMed ID: 10934884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
    Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
    Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of minimal residual leukemia using polymerase chain reaction method].
    Naoe T
    Rinsho Byori; 1996 Jun; 44(6):535-40. PubMed ID: 8752731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunoglobulin super-gene family and its related genes in detecting MRD in ALL].
    Dong S; Kuang S; Huang W
    Zhonghua Yi Xue Za Zhi; 1996 Oct; 76(10):742-6. PubMed ID: 9275514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
    Pongers-Willemse MJ; Seriu T; Stolz F; d'Aniello E; Gameiro P; Pisa P; Gonzalez M; Bartram CR; Panzer-Grümayer ER; Biondi A; San Miguel JF; van Dongen JJ
    Leukemia; 1999 Jan; 13(1):110-8. PubMed ID: 10049045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of minimal residual disease in B-cell lineage acute lymphoblastic leukemia of childhood, using clone-specific probes.
    Botsonis T; Tsangaris GT; Mikraki V; Tzortzatou-Stathopoulou F
    Anticancer Res; 1999; 19(3B):2211-20. PubMed ID: 10472333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between TaqMan and LightCycler technologies for quantification of minimal residual disease by using immunoglobulin and T-cell receptor genes consensus probes.
    Eckert C; Scrideli CA; Taube T; Songia S; Wellmann S; Manenti M; Seeger K; Biondi A; Cazzaniga G
    Leukemia; 2003 Dec; 17(12):2517-24. PubMed ID: 14562127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.
    van Dongen JJ; Macintyre EA; Gabert JA; Delabesse E; Rossi V; Saglio G; Gottardi E; Rambaldi A; Dotti G; Griesinger F; Parreira A; Gameiro P; Diáz MG; Malec M; Langerak AW; San Miguel JF; Biondi A
    Leukemia; 1999 Dec; 13(12):1901-28. PubMed ID: 10602411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.